Data completeness
0/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HISERPIA (reserpine) is an oral tablet formulation of reserpine, a Rauwolfia alkaloid antihypertensive agent. This NDA product from Teva is in pre-launch stage and is indicated for blood pressure management. Reserpine works by depleting catecholamine stores in the sympathetic nervous system, producing a gradual reduction in blood pressure.
PRE_LAUNCH
Pre-launch phase indicates significant opportunity for brand building and market education, but modest commercial scale expected given reserpine's historical decline in modern hypertension management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HISERPIA offers exposure to pre-launch commercialization strategy and market re-entry challenges for a legacy mechanism in a crowded therapeutic class. Career value lies in payer negotiation, narrow patient segmentation, and brand positioning rather than innovative science or clinical development.
Brand ManagerField Sales Representative
Worked on HISERPIA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.